Literature DB >> 2358848

Intra-arterial BCNU in the treatment of recurrent medulloblastoma.

K Watne1, B Hager, H Hirschberg.   

Abstract

Two patients with recurrent medulloblastomas were treated with combined oral and intravenous chemotherapy followed by intra-arterial BCNU. The 7 days course of oral and intra-venous chemotherapy consisted of CCNU and Procarbazin orally and Vincristine intravenously (PCV), repeated after 6 weeks. Intra-arterial chemotherapy consisted of 4 cycles of BCNU. Both patients responded well to treatment, evaluated by CT scans. One of the patients died of a new local recurrence 6 months after initiation of chemotherapy, whereas the other patient remains well, without CT evidence of tumour 36 months after the start of the treatment. No serious adverse side-effects related to the treatment were seen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2358848     DOI: 10.1007/bf00177836

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

1.  Medulloblastoma of the cerebellum, with survival for 17 years.

Authors:  W PENFIELD; W FEINDEL
Journal:  Arch Neurol Psychiatry       Date:  1947-04

2.  [Progress in the therapy of medulloblastoma].

Authors:  M Wannenmacher; H Knüfermann
Journal:  Onkologie       Date:  1978-06

3.  Medulloblastoma: an analysis of time-dose relationships and recurrence patterns.

Authors:  C E Smith; D M Long; T K Jones; S H Levitt
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

4.  The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases.

Authors:  H J Bloom; E N Wallace; J M Henk
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1969-01

5.  Radiation treatment for medulloblastoma. A 21-year review.

Authors:  M P Berry; R D Jenkin; C W Keen; B D Nair; W J Simpson
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

6.  Period of risk for recurrence in medulloblastoma.

Authors:  D O Quest; R Brisman; J L Antunes; E M Housepian
Journal:  J Neurosurg       Date:  1978-02       Impact factor: 5.115

7.  Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine.

Authors:  D C Crafts; V A Levin; M S Edwards; T L Pischer; C B Wilson
Journal:  J Neurosurg       Date:  1978-10       Impact factor: 5.115

8.  Medulloblastoma in children. Survival and treatment.

Authors:  J Mealey; P V Hall
Journal:  J Neurosurg       Date:  1977-01       Impact factor: 5.115

9.  Cerebellar medulloblastoma: the importance of posterior fossa dose to survival and patterns of failure.

Authors:  C L Silverman; J R Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-11       Impact factor: 7.038

10.  Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources.

Authors:  P H Gutin; T L Phillips; W M Wara; S A Leibel; Y Hosobuchi; V A Levin; K A Weaver; S Lamb
Journal:  J Neurosurg       Date:  1984-01       Impact factor: 5.115

View more
  2 in total

1.  Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.

Authors:  F H Tomlinson; M G Lihou; P J Smith
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

Review 2.  Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

Authors:  Rianne Haumann; Jessica Carvalho Videira; Gertjan J L Kaspers; Dannis G van Vuurden; Esther Hulleman
Journal:  CNS Drugs       Date:  2020-09-23       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.